Key result
Systemic sclerosis is linked to ~15% higher serum PPAR-γ versus controls, peaking in diffuse subtypes.
Why the study?
PPAR-γ may link cell metabolism and fibrosis in systemic sclerosis due to its anti-fibrotic and immunomodulatory properties, but its circulating levels in SSc patients were not well characterized.
Are serum levels of PPAR-γ elevated in patients with systemic sclerosis compared to healthy controls?
Case-Control (n=36)
No
Are serum levels of PPAR-γ elevated in patients with systemic sclerosis compared to healthy controls?
Absolute Event Rate: 15.98% vs 13.92%
p-value: p=0.007
Circulating PPAR-γ is elevated in systemic sclerosis, particularly in the diffuse subtype, suggesting a potential role in the disease's fibrotic or vascular pathogenesis.
Elevated PPAR-γ may mark systemic sclerosis activity; hypothesis-generating for pathogenesis and requires prospective validation before any clinical use.
Introduction: Systemic sclerosis (SSc) is an autoimmune connective tissue disease with distinguished fibrosis of the skin and internal organs.Vascular damage, immune dysregulation and fibroblasts activation contribute to SSc pathogenesis.Peroxisome proliferator-activated receptor γ (PPAR-γ) can be a link between cell metabolism and fibrosis in SSc due to its anti-fibrotic and immunomodulatory properties.Aim: To measure the serum level of PPAR-γ in SSc patients and correlate it with the SSc subtype, hs-CRP, disease duration, vascular and internal organ involvement.Material and methods: Twenty-two SSc patients (15 limited SSc, 7 diffuse SSc) matched with healthy controls were analysed.Clinical and laboratory data were collected including specific antibodies, interstitial lung disease, oesophageal involvement, digital pitting scars, disease duration, Raynaud's phenomenon (RP) and modified Rodnan skin score (mRSS).PPAR-γ levels were analysed by ELISA.Statistical analysis was performed with c 2 , Student's t-test and Mann-Whitney-U test.Pearson and Spearman correlation analyses were used to establish variables association.The significance threshold was set at p < 0.05.Results: PPAR-γ concentration was elevated in SSc patients in comparison to controls (p = 0.007) with the highest difference for diffuseSSc (p = 0.004) with significantly elevated mRSS.No association between PPAR-γ levels and hs-CRP, internal organ and vascular involvement, disease duration, autoantibodies and RP onset was found.Conclusions: The present study revealed elevated serum PPAR-γ in SSc patients, in particular those with a diffuse form, presenting highest mRSS and lowest BMI.Whether circulating PPAR-γ originates from atrophic adipose tissue, reperfused vessels or ischemic tissues needs assessing.Also the biological meaning or effect of elevated serum PPAR-γ requires further studies.
No takes yet. Share an insight, caveat, or question.
Żółkiewicz et al. (2019) conducted a case-control in Systemic sclerosis (n=36). Systemic sclerosis vs. Healthy controls was evaluated on Serum PPAR-γ concentration (ng/ml) (p=0.007). Patients with systemic sclerosis had significantly elevated serum PPAR-γ concentrations compared to healthy controls (15.98 vs 13.92 ng/ml, p=0.007), with the highest levels observed in the diffuse subtype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: